Market News
Smart Trading. Simplified.
Tiny Biotech Creates $2 Trillion Drug
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
Is Walmart A Good Dividend Stock?
Walmart is the world’s largest retailer. In the U.S., its name alone is practically a byword for affordable and hassle-free shopping. But does the company make for a good dividend stock, and is it worth investing in at the current time? Walmart’s Dividend History It’s said that a good dividend stock is one you buy […]
Jeff Bezos' Next Big Thing
The tech visionary who built a revolutionary $1.6 trillion company from scratch is quietly pouring his riches into a secretive project that could mean the end of Alzheimer's.
Early investors who get in by June 2, 2021, could turn every $1,000 into $1.1 million.
Is YOLO ETF A Good Investment?
Lately there’s been quite a lot of interest in a fund called YOLO ETF. The official name is the Advisorshares Pure Cannabis ETF, but the nickname, (and the ticker name) just caught on. What Is YOLO ETF? Simply put, YOLO ETF is the first actively managed exchange traded fund or ETF with a dedication to […]
The World's First $2 Trillion Drug?
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
Kevin Paffrath California Governor
Kevin Paffrath, who goes professionally by the name Meet Kevin, is a real estate investor and landlord. He has used his experience in these and related investment fields to grow a popular YouTube channel called Meet Kevin. Paffrath announced in 2021 that he was running against Gavin Newsom for governor of California. Paffrath and Newsom are […]
Profit-Alert: Tiny Gold Firm Hits Paydirt Next to Industry Giants
Smart investors are loading up on a tiny gold exploration firm - trading below 50 cents a share - that's developing not one but two gold projects in Nevada's famed Carlin Trend. Its flagship project is right next door to a giant discovery by industry behemoths Barrick and Newmont. With multiple drill rigs and nearly half a million ounces already discovered, 10-fold upside may prove conservative.
Will Tal Education Stock Recover?
Tal Education (TAL) is a Chinese company that provides tutoring services. The price action of TAL has been volatile over the past year, and many are wondering whether this is a good entry point. So what’s the deal with Tal Education? Why did its share price plummet and will Tal stock recover? The acronym “TAL,” […]
Power Your Portfolio With Advanced Forecasting
Go after the same opportunities as the ultra-rich by using market forecasting so you can find the best trades. This breakthrough technology helps you build a more secure financial future because it removes all guesswork.
For a limited time, see a LIVE demonstration of the technology specifically made to help independent traders jump on trends at the most opportune time.
Moderna Stock Vs Inovio: Which Is Best?
Moderna Stock Vs Inovio: The research and development of COVID-19 vaccines throughout the novel coronavirus pandemic has absolutely rocked the pharmaceutical industry, but it’s also had quite the impact on the stock market. With several pharmaceutical companies competing for the best vaccine on the market and others doing their best to join in the competition […]
The World's First $20 Trillion Drug?
One small biotech holds the key to a revolution in treating Alzheimer's. Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.
Our research shows that anyone who gets in by June 2, 2021 could turn every $1,000 into $1.1 million.
Early investors who get in by June 2, 2021, could turn every $1,000 into $1.1 million.
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment